Marengo Therapeutics Welcomes Dr. Elena Garralda to Its Scientific Advisory Board in 2025
Marengo Therapeutics, a pioneering clinical-stage biotechnology company focused on precision immunotherapy in oncology, has announced the significant appointment of Dr. Elena Garralda, MD, PhD, to its Scientific Advisory Board (SAB). This strategic decision, which reflects the company’s dedication to advancing cancer treatment methodologies, aims to leverage Dr. Garralda’s extensive expertise in early-phase clinical trials and translational oncology research.
Dr. Garralda holds the position of Director of Early Drug Development at Vall d'Hebron University Hospital (VHIO) in Barcelona and leads the Phase I Unit at NEXT Oncology. Recognized internationally for her contributions to the field, Dr. Garralda is anticipated to provide invaluable insights and guidance within the SAB, which is co-chaired by eminent figures in oncology research, Dr. E. John Wherry and Dr. James L. Gulley, alongside fellow members like Dr. Lillian L. Siu and Dr. Howard Kaufman.
The Chief Executive Officer of Marengo Therapeutics, Zhen Su, expressed enthusiasm about Dr. Garralda’s acceptance into the advisory board, emphasizing that her exceptional leadership and contributions align seamlessly with the company’s mission to translate innovative biology into impactful treatments. “We are thrilled to have Dr. Garralda joining our team. Her deep understanding of translational oncology and clinical development will be instrumental as we continue on our path to accelerate the development of transformative immunotherapies,” said Su.
Dr. Garralda’s role in shaping the scientific and clinical strategies of Marengo Therapeutics cannot be overstated. Her participation in the SAB will reportedly enhance the company’s ability to drive innovation, strengthen the connection between scientific research and clinical application, and ultimately advance their treatment pipeline to benefit cancer patients globally.
“I am honored to join this distinguished team of scientific and clinical experts,” Dr. Garralda remarked about her new role. “Marengo’s innovative approach to harnessing the immune system is incredibly promising for the development of new therapies. I am excited to contribute to advancing these groundbreaking programs.”
Marengo Therapeutics, Inc. is committed to developing novel TCR-targeting antibodies aimed at selectively modulating specific T cell subsets, thereby creating a more robust defense system against cancer and other diseases. Through its proprietary Selective T Cell Activation Repertoire (STAR) platform, Marengo Therapeutics combines a profound understanding of T cell biology with cutting-edge immunology to realize the goal of empowering all individuals' immune systems to combat cancer effectively.
In light of this new appointment, Marengo continues to strengthen its commitment to innovation in cancer treatment, working diligently to enhance the lives of patients worldwide. For those interested in learning more about the company's mission and its groundbreaking therapies, further information is available on their website, marengotx.com.
In summary, the appointment of Dr. Garralda to Marengo Therapeutics’ Scientific Advisory Board marks a significant step forward in the company's journey towards revolutionizing immunotherapy and improving outcomes for cancer patients everywhere.
Dr. Garralda holds the position of Director of Early Drug Development at Vall d'Hebron University Hospital (VHIO) in Barcelona and leads the Phase I Unit at NEXT Oncology. Recognized internationally for her contributions to the field, Dr. Garralda is anticipated to provide invaluable insights and guidance within the SAB, which is co-chaired by eminent figures in oncology research, Dr. E. John Wherry and Dr. James L. Gulley, alongside fellow members like Dr. Lillian L. Siu and Dr. Howard Kaufman.
The Chief Executive Officer of Marengo Therapeutics, Zhen Su, expressed enthusiasm about Dr. Garralda’s acceptance into the advisory board, emphasizing that her exceptional leadership and contributions align seamlessly with the company’s mission to translate innovative biology into impactful treatments. “We are thrilled to have Dr. Garralda joining our team. Her deep understanding of translational oncology and clinical development will be instrumental as we continue on our path to accelerate the development of transformative immunotherapies,” said Su.
Dr. Garralda’s role in shaping the scientific and clinical strategies of Marengo Therapeutics cannot be overstated. Her participation in the SAB will reportedly enhance the company’s ability to drive innovation, strengthen the connection between scientific research and clinical application, and ultimately advance their treatment pipeline to benefit cancer patients globally.
“I am honored to join this distinguished team of scientific and clinical experts,” Dr. Garralda remarked about her new role. “Marengo’s innovative approach to harnessing the immune system is incredibly promising for the development of new therapies. I am excited to contribute to advancing these groundbreaking programs.”
Marengo Therapeutics, Inc. is committed to developing novel TCR-targeting antibodies aimed at selectively modulating specific T cell subsets, thereby creating a more robust defense system against cancer and other diseases. Through its proprietary Selective T Cell Activation Repertoire (STAR) platform, Marengo Therapeutics combines a profound understanding of T cell biology with cutting-edge immunology to realize the goal of empowering all individuals' immune systems to combat cancer effectively.
In light of this new appointment, Marengo continues to strengthen its commitment to innovation in cancer treatment, working diligently to enhance the lives of patients worldwide. For those interested in learning more about the company's mission and its groundbreaking therapies, further information is available on their website, marengotx.com.
In summary, the appointment of Dr. Garralda to Marengo Therapeutics’ Scientific Advisory Board marks a significant step forward in the company's journey towards revolutionizing immunotherapy and improving outcomes for cancer patients everywhere.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.